Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.

Chan JK, Kiet TK, Blansit K, Ramasubbaiah R, Hilton JF, Kapp DS, Matei D.

Gynecol Oncol. 2014 Jun;133(3):568-74. doi: 10.1016/j.ygyno.2014.03.564. Epub 2014 Mar 25.

PMID:
24680769
2.

miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.

Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G.

J Natl Cancer Inst. 2013 Nov 20;105(22):1750-8. doi: 10.1093/jnci/djt302. Epub 2013 Oct 29.

PMID:
24168967
3.

Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.

Fan Y, Fan J, Huang L, Ye M, Huang Z, Wang Y, Li Q, Huang J.

Int J Clin Exp Pathol. 2015 Apr 1;8(4):4132-7. eCollection 2015.

4.

Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.

Steffensen KD, Madsen CV, Andersen RF, Waldstrøm M, Adimi P, Jakobsen A.

Eur J Cancer. 2014 Oct;50(15):2611-8. doi: 10.1016/j.ejca.2014.06.022. Epub 2014 Jul 30.

PMID:
25087181
5.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

6.

MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer.

Wang X, Meng X, Li H, Liu W, Shen S, Gao Z.

Clin Transl Oncol. 2014 Nov;16(11):954-8. doi: 10.1007/s12094-014-1178-6. Epub 2014 Apr 3.

PMID:
24696291
7.

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.

8.

Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.

Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, Tonini G.

Eur J Cancer. 2013 Apr;49(6):1501-8. doi: 10.1016/j.ejca.2012.11.014. Epub 2012 Dec 22.

PMID:
23266047
9.

Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.

Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW, Ahn WS.

Drug Des Devel Ther. 2014 Feb 24;8:293-314. doi: 10.2147/DDDT.S51969. eCollection 2014.

10.

Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.

Peng DX, Luo M, Qiu LW, He YL, Wang XF.

Oncol Rep. 2012 Apr;27(4):1238-44. doi: 10.3892/or.2012.1625. Epub 2012 Jan 11.

11.

Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer.

Wang S, Li Q, Wang K, Dai Y, Yang J, Xue S, Han F, Zhang Q, Liu J, Wu W.

Clin Transl Oncol. 2013 Oct;15(10):849-54. doi: 10.1007/s12094-013-1014-4. Epub 2013 Feb 14.

PMID:
23408039
12.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul.

13.

Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.

Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Fuso Nerini I, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M.

Lancet Oncol. 2011 Mar;12(3):273-85. doi: 10.1016/S1470-2045(11)70012-2. Epub 2011 Feb 21.

PMID:
21345725
14.

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.

Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, Provencio M, Alvarez-Vallina L, Sanz L.

Med Oncol. 2013;30(2):572. doi: 10.1007/s12032-013-0572-1. Epub 2013 Apr 12.

PMID:
23579861
15.

Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.

Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH.

Oncogene. 2012 Feb 9;31(6):764-75. doi: 10.1038/onc.2011.269. Epub 2011 Jul 4.

PMID:
21725366
16.

[Effects of miR-135a on HOXA10 expression, proliferation and apoptosis of ovarian cancer cells].

Tang WW, Wan GP, Wan YC, Zhang L, Cheng WJ.

Zhonghua Fu Chan Ke Za Zhi. 2013 May;48(5):364-9. Chinese.

PMID:
24016480
17.

The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.

Chan JK, Blansit K, Kiet T, Sherman A, Wong G, Earle C, Bourguignon LY.

Gynecol Oncol. 2014 Mar;132(3):739-44. doi: 10.1016/j.ygyno.2014.01.034. Epub 2014 Jan 25.

PMID:
24472409
18.

[Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis].

Li J, Liang SH, Lu X.

Zhonghua Fu Chan Ke Za Zhi. 2010 Oct;45(10):787-92. Chinese.

PMID:
21176563
19.

Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.

Pentheroudakis G, Kotoula V, Kouvatseas G, Charalambous E, Dionysopoulos D, Zagouri F, Koutras A, Papazisis K, Pectasides D, Samantas E, Dimopoulos MA, Papandreou CN, Fountzilas G.

Clin Breast Cancer. 2014 Oct;14(5):330-8. doi: 10.1016/j.clbc.2014.02.009. Epub 2014 Mar 1.

PMID:
24703319
20.

Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.

Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, Nelson T, McMeekin DS, Moore KN.

Gynecol Oncol. 2014 Apr;133(1):11-5. doi: 10.1016/j.ygyno.2014.01.031.

PMID:
24680585

Supplemental Content

Support Center